Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
复制标题
DOI：
10.1038/nm0398-321
复制
发表时间：
1998-03-01
期刊：
影响因子：
82.9
通讯作者：
White, DE
中科院分区：
文献类型：
--
作者：
Rosenberg, SA;Yang, JC;White, DE
编码癌症抗原的基因的克隆为癌症患者的治疗开辟了新的可能性。在这项研究中，我们鉴定了来自gp100黑色素瘤相关抗原的免疫优势多肽，并将一种旨在增加与人类白细胞抗原A2分子结合的合成肽用作癌症疫苗来治疗转移性黑色素瘤患者。在免疫学检测的基础上，91%的患者可以成功地用该合成肽免疫，在31例接受多肽疫苗和IL-2的患者中，有13例(42%)有客观的癌症反应，另有4例患者有混合或轻微反应。基于肿瘤抗原编码基因的合成肽疫苗为新型癌症免疫疗法的发展提供了希望。
The cloning of the genes encoding cancer antigens has opened new possibilities far the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic-peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.